362 related articles for article (PubMed ID: 23376850)
1. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
2. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
4. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.
Cao Y; Mohamedali KA; Marks JW; Cheung LH; Hittelman WN; Rosenblum MG
Mol Cancer Ther; 2013 Jun; 12(6):979-91. PubMed ID: 23493312
[TBL] [Abstract][Full Text] [Related]
6. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Rosenblum MG; Cheung LH; Liu Y; Marks JW
Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
[TBL] [Abstract][Full Text] [Related]
8. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
9. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
[TBL] [Abstract][Full Text] [Related]
11. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
[TBL] [Abstract][Full Text] [Related]
12. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
13. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Mazor Y; Noy R; Wels WS; Benhar I
Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
[TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
16. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
18. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
[TBL] [Abstract][Full Text] [Related]
19. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]